Zoetis Inc. shares underperformed in the second quarter of 2026 after the animal health company reported flat organic revenue growth and lowered its full-year guidance amid softening US companion-animal demand, fewer veterinary visits, and a more competitive market. Diamond Hill Capital's Large Cap Strategy noted that these results heightened concerns that slowing growth in the legacy portfolio could create a near-term earnings gap before newer pipeline products contribute more meaningfully. The stock closed at $77.29 on July 31, 2026, with a one-month return of 6.98% and a 52-week loss of 47.91%, giving the company a market capitalization of about $32.40 billion. The number of hedge funds holding Zoetis fell to 57 in the first quarter from 69 in the prior quarter.
Zoetis IncFlat organic revenue growth and lowered guidance due to softening US companion-animal demand and fewer veterinary visits.